Arcus Biosciences, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $502.0M | $173.4M |
| FY2021 | — | $842.0M | $148.0M |
| FY2022 | — | $657.0M | $206.0M |
| FY2023 | $0 | $462.0M | $127.0M |
| FY2024 | $48.0M | $485.0M | $150.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $502.0M | $173.4M |
| FY2021 | — | $842.0M | $148.0M |
| FY2022 | — | $657.0M | $206.0M |
| FY2023 | $0 | $462.0M | $127.0M |
| FY2024 | $48.0M | $485.0M | $150.0M |